You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 20, 2025

Details for Patent: 10,149,829


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,149,829
Title:Treatment of circadian rhythm disorders
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s): Dressman; Marlene Michelle (Germantown, MD), Feeney; John Joseph (Olney, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee: Vanda Pharmaceuticals Inc. (Washington, DC)
Application Number:15/382,526
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,149,829
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,149,829

Introduction to Patent 10,149,829

United States Patent 10,149,829, hereafter referred to as the '829 patent, is one of the patents asserted by Vanda Pharmaceuticals, Inc. in the case Vanda Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.. This patent is related to Vanda's drug product HetliozĀ®, which is the only FDA-approved drug for the treatment of Non-24-Hour Sleep-Wake Disorder.

Background of the Patent

The '829 patent is part of a series of patents held by Vanda Pharmaceuticals that pertain to the formulation, use, and administration of tasimelteon, the active ingredient in HetliozĀ®. These patents are crucial for Vanda's intellectual property protection and market exclusivity.

Claims of the Patent

The '829 patent includes several claims that define the scope of the invention. Here are some key aspects of these claims:

Claim Structure

  • The claims in the '829 patent are structured to cover various aspects of the drug, including its composition, method of use, and specific dosages.
  • For example, Claim 14 of the '829 patent, which was challenged in the court case, depends on Claim 13 and specifies particular formulations and administration methods of tasimelteon[5].

Dependency Between Claims

  • The claims in the patent are often dependent on each other, meaning that a dependent claim incorporates all the limitations of the independent claim from which it depends.
  • This structure is designed to provide a comprehensive protection of the invention by covering different facets of it[5].

Patent Landscape and Prior Art

Prior Art References

  • The validity of the '829 patent was challenged based on prior art references, including publications by Hack, Lankford, Hardeland, and Pandi-Perumal.
  • The court considered whether these references, when combined, would render the claimed invention obvious to a person of ordinary skill in the art[5].

Global Dossier and International Patent Offices

  • When analyzing the patent landscape, it is essential to consider international patent offices and global dossier services.
  • Tools like the Global Dossier provided by the USPTO allow users to view the patent family for a specific application, including related applications filed at participating IP Offices, which can help in identifying prior art and potential challenges to patent validity[1].

Court Ruling and Validity

Obviousness

  • The district court in Vanda Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. held that all asserted patent claims, including those of the '829 patent, were invalid for obviousness.
  • The court found that the combination of prior art references suggested a reasonable expectation of success, which is a key factor in determining obviousness[5].

Nexus Between Evidence and Invention

  • For objective evidence to support the validity of a patent, there must be a legally and factually sufficient connection (nexus) between the evidence and the merits of the invention.
  • In the case of the '829 patent, the court found that the objective evidence presented did not establish this necessary nexus, leading to the invalidation of the claims[5].

Search and Analysis Tools

USPTO Resources

  • Conducting a thorough search of existing patents and prior art is crucial for determining the validity and scope of a patent.
  • The USPTO provides several tools, including the Patent Public Search, Global Dossier, and Patent and Trademark Resource Centers (PTRCs), which can be used to search for prior art and analyze the patent landscape[1].

International Databases

  • Searching international patent databases, such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and World Intellectual Property Organization (WIPO), is also essential for a comprehensive analysis[1].

Economic and Strategic Implications

Patent Scope and Claims

  • The scope and claims of a patent like the '829 patent have significant economic and strategic implications.
  • A patent with broad and valid claims can provide strong market protection and exclusivity, while narrow or invalid claims can leave the invention vulnerable to competition[3].

Research Datasets

  • The USPTO's Patent Claims Research Dataset can provide valuable insights into patent scope and claims.
  • This dataset contains detailed information on claims from US patents and applications, which can be used to analyze trends and strategies in patenting[3].

Best Practices for Patent Search and Analysis

Preliminary Search

  • Before filing a patent application, it is advisable to conduct a preliminary search using tools like the Patent Public Search and Global Dossier.
  • This helps in identifying prior art and potential issues with the patent's validity[1].

Expert Assistance

  • Utilizing the expertise of trained staff at the USPTO Public Search Facility or Patent and Trademark Resource Centers can be beneficial in conducting thorough searches and analyzing the patent landscape[1].

Key Takeaways

  • Comprehensive Search: Conducting a thorough search of prior art using various USPTO resources and international databases is crucial for determining the validity and scope of a patent.
  • Claim Structure: Understanding the dependency between claims and the specific limitations of each claim is essential for analyzing the patent's scope.
  • Court Rulings: Court decisions, such as the one in Vanda Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc., highlight the importance of establishing a nexus between objective evidence and the claimed invention.
  • Economic Implications: The scope and validity of a patent have significant economic and strategic implications for the holder.

FAQs

Q: What is the significance of the '829 patent in the context of Vanda Pharmaceuticals?

  • The '829 patent is one of the key patents held by Vanda Pharmaceuticals related to its drug product HetliozĀ®, providing market exclusivity and intellectual property protection.

Q: Why was the '829 patent invalidated by the court?

  • The court held that the claims of the '829 patent were invalid for obviousness based on prior art references that suggested a reasonable expectation of success.

Q: What tools can be used to search for prior art related to a patent?

  • Tools such as the USPTO's Patent Public Search, Global Dossier, and international patent databases like those provided by the EPO and WIPO can be used to search for prior art.

Q: How important is establishing a nexus between objective evidence and the claimed invention?

  • Establishing a nexus is crucial for supporting the validity of a patent, as it ensures that the objective evidence is directly related to the merits of the invention.

Q: What are the economic implications of a patent being invalidated?

  • The invalidation of a patent can lead to loss of market exclusivity and significant economic impacts on the patent holder, as it opens the market to generic competitors.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,149,829

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 10,149,829 ⤷  Try for Free TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS ⤷  Try for Free
Vanda Pharms Inc HETLIOZ tasimelteon CAPSULE;ORAL 205677-001 Jan 31, 2014 AB RX Yes Yes 10,149,829 ⤷  Try for Free TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS ⤷  Try for Free
Vanda Pharms Inc HETLIOZ LQ tasimelteon SUSPENSION;ORAL 214517-001 Dec 1, 2020 RX Yes Yes 10,149,829 ⤷  Try for Free TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,149,829

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013211878 ⤷  Try for Free
Australia 2013211880 ⤷  Try for Free
Australia 2013361459 ⤷  Try for Free
Australia 2015206797 ⤷  Try for Free
Australia 2016204178 ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.